Drugs / TPX-100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06865079 | May 2025 → Mar 2027 expected | osteoarthritis, knee | OrthoTrophix, Inc | Active not recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT02837900 Comparator | Aug 2016 → Aug 2017 | osteoarthritis, knee | OrthoTrophix, Inc | Completed | No outcome recorded |
| Phase 2 | NCT01925261 Comparator | Jan 2014 → Sep 2016 | osteoarthritis, knee | OrthoTrophix, Inc | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 12
| Date | Issuer | Release |
|---|---|---|
| 2022-04-08 | OrthoTrophix, Inc | Results TPX-100: OrthoTrophix Presents New Data Suggesting Joint Bone Shape as a Possible Surrogate Marker for Virtual Joint Replacement in Knee Osteoarthritis orthotrophix.com ↗
Consequently, both clinical (knee function) and structural (bone shape) efficacies of TPX-100 as compared to placebo were confirmed including in subjects with moderate to severe knee OA. |
| 2021-09-21 | OrthoTrophix, Inc | Results TPX-100: OrthoTrophix Published a New Research Article Demonstrating Disease Modification in Knee Osteoarthritis orthotrophix.com ↗ |
| 2020-05-12 | OrthoTrophix, Inc | Results TPX-100: OrthoTrophix Presents More Evidence for Disease Modification in Knee Osteoarthritis in a New Abstract Published in Osteoarthritis & Cartilage Journal orthotrophix.com ↗
As now reported, the reduced pathological 3D shape changes in the femur were significantly correlated with stabilization of tibiofemoral cartilage thickness in the TPX-100-treated knees (p<0.01), but not in placebo-treated knees. |
| 2020-03-02 | OrthoTrophix, Inc | Results TPX-100: OrthoTrophix Demonstrates Evidence for Disease Modification in Knee Osteoarthritis orthotrophix.com ↗
TPX-100-treated knees demonstrated clinically meaningful and statistically significant improvement in critical knee functions, based on 17 measures, as compared to placebo-treated knees by 6 months, with benefits maintained through 12 months (Figure 1). |
| 2019-11-09 | OrthoTrophix, Inc | Results OrthoTrophix Presents Evidence for Disease Modification in Knee Osteoarthritis by TPX-100 at American College of Rheumatology Annual Meeting orthotrophix.com ↗
OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today that TPX-100 treatment is associated with significant decreases in MRI-based structural pathology in knee OA compared with placebo. |
| 2019-06-12 | OrthoTrophix, Inc | Results OrthoTrophix Presents Clinical Data at European Congress of Rheumatology Demonstrating Significant Correlation between Knee Function Improvement and Cartilage Thickness Increase/Stabilization after TPX-100 orthotrophix.com ↗
Knee function, measured by the Knee injury and Osteoarthritis Outcome Score (KOOS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at 6 and 12 months, was markedly improved in TPX-100-treated knees compared to placebo-exposed knees. |
| 2019-06-10 | OrthoTrophix, Inc | Results Reduction in Pathological Bone Shape Change Correlates with Decreased Frequency of Knee Pain after TPX-100 Treatment orthotrophix.com ↗
OrthoTrophix, Inc., a privately-held biopharmaceutical company, announced today new results from a Phase 2 study of the osteoarthritis drug TPX-100. |
| 2019-05-13 | OrthoTrophix, Inc | Results TPX-100 Delays Pathological Changes of Bone in Osteoarthritis of the Knee orthotrophix.com ↗
The new results indicate slowing or halting of pathological bone shape changes, findings that support structural disease modification by TPX-100 treatment. |
| 2018-10-23 | OrthoTrophix, Inc | Results OrthoTrophix Presents Knee Cartilage Structure Modification Data of TPX-100 at American College of Rheumatology Annual Meeting orthotrophix.com ↗
OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today that the company and its collaborators presented the Phase 2 clinical study data of TPX-100 demonstrating structural improvement of knee cartilage associated with robust knee function improvement in knee osteoarthritis (OA) patients at the American College of Rheumatology (ACR/ARHP) Annual Meeting in Chicago, IL. |
| 2018-08-13 | OrthoTrophix, Inc | Results Clinical Benefits of TPX-100 in Knee Osteoarthritis Patients are Associated with Improvements in Knee Cartilage Structure Modification orthotrophix.com ↗
OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today results of a post-hoc responder analysis of the Phase 2 clinical study with TPX-100, the company’s osteoarthritis (OA) drug candidate. |
| 2017-11-07 | OrthoTrophix, Inc | Results OrthoTrophix Presents the Key Data of the TPX-100 Phase 2 Study as a Late Breaking Abstract at American College of Rheumatology Annual Meeting orthotrophix.com ↗ |
| 2016-12-15 | OrthoTrophix, Inc | Results Significant Improvements in Knee Function after TPX-100 Administration in a Double-Blind, Placebo-Controlled Phase 2 Study of Knee Osteoarthritis orthotrophix.com ↗
In the whole study population, knee function was significantly improved in TPX-100-treated knees compared with controls. |
All press releases naming this drug 16 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TPX-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01925261 ↗ |
| Modality | Peptide | “TPX-100, a 23-amino acid chondrogenic peptide” NCT01925261 ↗ |
| Route | Other | “administered by intra-articular injection” NCT02837900 ↗ |